246529-22-6|Aramchol|(R)-4-((3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-icosanamido-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid|-范德生物科技公司

Aramchol

NMR下载 COA and HPLC MSDS下载
names：
(R)-4-((3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-icosanamido-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
CAS号：
246529-22-6
MDL Number：
MF(分子式)： C44H79NO5 MW(分子量)： 702.118
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Aramchol
英文别名	Aramchol; Arachidyl amido cholanoic acid;
CAS号	246529-22-6
SMILES	CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]3[C@@H]2C[C@@H]([C@]4([C@H]3CC[C@@H]4[C@H](C)CCC(=O)O)C)O)O)C
Inchi	InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
InchiKey	SHKXZIQNFMOPBS-OOMQYRRCSA-N
分子式 Formula	C44H79NO5
分子量 Molecular Weight	702.118
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Aramchol(CAS:246529-22-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Aramchol, also known as Arachidyl amido cholanoic acid, is a cholesterol solubilizer that prevents gallstone formation in inbred mice. Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group.. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e[1]doi: 10.1016/j.cgh.2014.04.038. PubMed PMID: 24815326.

[2]Leikin-Frenkel A, Weinbroum AA, Leikin-Gobbi D, Krupitzky L, Goldiner I, Shafat L, Gilat T, Konikoff FM. Faecal sterol output is increased by arachidyl amido cholanoic acid (Aramchol) in rats. Biochem Soc Trans. 2004 Feb;32(Pt 1):131-3. PubMed PMID: 14748731.

[3] Gilat T, Leikin-Frenkel A, Goldiner L, Laufer H, Halpern Z, Konikoff FM. Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice. Lipids. 2001 Oct;36(10):1135-40. PubMed PMID: 11768158.

[4] Leikin-Frenkel A, Gonen A, Shaish A, Goldiner I, Leikin-Gobbi D, Konikoff FM, Harats D, Gilat T. Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic. Arch Med Res. 2010 Aug;41(6):397-404. doi: 10.1016/j.arcmed.2010.09.001. PubMed PMID: 21044742.

[5] Goldiner I, van der Velde AE, Vandenberghe KE, van Wijland MA, Halpern Z, Gilat T, Konikoff FM, Veldman RJ, Groen AK. ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs). Biochem J. 2006 Jun 15;396(3):529-36. PubMed PMID: 16522192; PubMed Central PMCID: PMC1482810.

6: Ratziu V. Novel Pharmacotherapy Options for NASH. Dig Dis Sci. 2016 May;61(5):1398-405. doi: 10.1007/s10620-016-4128-z. Review. PubMed PMID: 27003143.7: Leikin-Frenkel A, Parini P, Konikoff FM, Benthin L, Leikin-Gobbi D, Goldiner I, Einarsson C, Gilat T. Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice. Arch Biochem Biophys. 2008 Mar 1;471(1):63-71. doi: 10.1016/j.abb.2007.12.005. PubMed PMID: 18167305.8: Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016 May;20(2):365-85. doi: 10.1016/j.cld.2015.10.015. Review. PubMed PMID: 27063275.9: Konikoff FM, Gilat T. Effects of fatty acid bile acid conjugates (FABACs) on biliary lithogenesis: potential consequences for non-surgical treatment of gallstones. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Jun;5(2):171-5. Review. PubMed PMID: 16089349.10: Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017 Jan;66(1):180-190. doi: 10.1136/gutjnl-2016-312431. Review. PubMed PMID: 27646933.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开